Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.62 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77446 | 1.00 | QPCT (0.62) | QPCTQPCTLPOLBNPC1SMN1; SMN2 | |
| SCHEMBL4566562 | 0.83 | QPCT (0.62) | QPCTQPCTLPOLBNPC1KMT2A | |
| SCHEMBL4569743 | 0.82 | QPCT (0.67) | QPCTQPCTLPOLBNPC1 | |
| SCHEMBL77447 | 0.76 | QPCT (1.00) | QPCTQPCTLPOLBKMT2A | |
| SCHEMBL77920 | 0.76 | QPCT (1.00) | QPCTQPCTLPOLBKMT2A | |
| SCHEMBL77445 | 0.76 | QPCT (1.00) | QPCTQPCTLPOLBKMT2A | |
| SCHEMBL76307 | 0.72 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL85717 | 0.70 | QPCT (0.73) | QPCTQPCTLPOLBNPC1KMT2A | |
| SCHEMBL78461 | 0.69 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL14855986 | 0.69 | QPCT (0.65) | QPCTQPCTLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2082041-B1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8647834-B2 | Screening method for enzyme inhibitors | PROBIODRUG AG (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2581449-A2 | Novel genes related to glutaminyl cyclase | Probiodrug AG (DE) | 2013-04-17 | — | — | EP | disclosed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-2481408-A2 | New use of glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120183974-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8129160-B2 | Method of screening for inhibitors of glutaminyl cyclase activity | PROBIODRUG AG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| EP-2117540-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-2082041-A2 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| WO-2008104580-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008034891-A2 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1713780-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | QPCT 2/4885QPCTL 11/4885POLB 1476/4885 |
| US-20090068699-A1 | USE OF GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLS | QPCT 1/4885QPCTL 15/4885POLB 2080/4885 |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLUL | QPCT 1/4885QPCTL 6/4885POLB 2345/4885 |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | QPCT 5/4885QPCTL 83/4885POLB 3053/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | QPCT 5/4885QPCTL 83/4885POLB 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.